


<b>Product Name</b>	: Rg3039
<b>Synonyms</b>	: RG3039; RG 3039; PF 06687859; PF-06687859
<b>Cat No.</b>	: M17746
<b>CAS Number</b>	: 1005504-62-0
<b>Molecular Formula</b>	: C <sub>21</sub> H <sub>23</sub> Cl <sub>2</sub> N <sub>5</sub> O
<b>Formula Weight</b>	: 432.35
<b>Chemical Name</b>	: 5-((1-(2,6-dichlorobenzyl)piperidin-4-yl)methoxy)quinazoline-2,4-diamine
<b>Description</b>	<p>RG3039, also known as PF-06687859, is a potent DcpS inhibitor. DcpS is a therapeutic target for spinal muscular atrophy. Spinal muscular atrophy (SMA) is caused by deletion or mutation of both copies of the SMN1 gene which produces an essential protein known as SMN. RG3039 improves motor function in SMA mice. RG3039 also showed activity to improve survival, function and motor unit pathologies in two SMA mouse models.</p>
<b>Pathway</b>	: Cell Cycle/DNA Damage
<b>Target</b>	: GPR
<b>Receptor</b>	: DcpS
<b>Solubility</b>	: DMSO : 6 mg/mL 13.88 mM; H <sub>2</sub> O : < 0.1 mg/mL
<b>SMILES</b>	: C1CN(CCC1COc1cccc2c1c(nc(n2)N)N)Cc1c(cccc1Cl)Cl
<b>Storage</b>	: (-20°C)
<b>Stability</b>	: ≥ 2 years
<b>Reference</b>	:



1. Rocky G. Gogliotti, et al. Hum Mol Genet. 2013 Oct 15; 22(20): 4084–4101.